Virginia Kaklamani, MD, UT Southwestern Medical Center, Dallas, TX, shares the updated results of the Phase III EMERALD (NCT03778931) trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer. The primary results had demonstrated that elacestrant was superior to standard endocrine therapy. This year at the San Antonio Breast Cancer Symposium (SABCS) 2022, results of the EMERALD trial were presented based on duration of prior CDK4/6i in the metastatic setting. The duration of prior CDK4/6i in the metastatic setting was positively associated with progression-free survival (PFS), the longer the duration of prior CDK4/6i in the metastatic setting, the longer the PFS on elacestrant versus standard of care. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
